Nicotine Replacement Therapy Market Overview
Nicotine Replacement Therapy Market was valued at US$ 50.4 billion in 2024 and is projected to grow at a CAGR of 13.70% to reach US$ 181.4 billion by 2034.
Nicotine Replacement Therapy (NRT) is a treatment which help people to stop smoking. In Nicotine Replacement Therapy product with low doses of nicotine is supplied. These products do not contain toxins which are found in smoke. Nicotine Replacement Therapy help in reducing the withdrawal feelings by giving a small controlled amount of nicotine. Small amount of nicotine helps in satisfying craving for nicotine & reduces urge to smoke. NRT is given in the form of sprays, inhalers, gum, patches, lozenges, etc. but no harmful chemicals in tobacco. NRT works by releasing a lower and more slowly absorbed dose of nicotine which is compared to smoking. NRT helps in minimizing withdrawal symptoms by reducing craving intensity & frequency. Chantix alone or combination of patch plus gum or lozenges are considered to be most effective options which help people to quit smoking. NRT deals with physical dependence. Nicotine patches are transdermal nicotine systems in which patches can be brought with or without prescription. Nicotine patches gives measured dose of nicotine through skin and an individual is weaned off nicotine by switching to lower dose patches over a course of week. 16-hour and 24-hour patches are available in different types and strengths. Which patch is to use is depended on how many cigarettes is smoke each day by an individual who is addicted to nicotine. US FDA has approved using patches for total of 3 to 5 months. Nicotine gum is nicotine polacrilex and can be brought without prescription. Nicotine gum is fast acting. Nicotine gum is taken through mucous membrane of mouth. Nicotine gum comes in 2mg and 4mg strength. Nicotine gum helps in allowing individual to control the amount of nicotine they get. Nicotine gum can be used as needed or at fixed schedule during the day. According to researchers scheduled dosing works better. Schedule of nicotine gum in 1 to 2 pieces per hour is common. However, rising awareness among individual against smoking has become the positive impact on target market growth.
Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.
Nicotine Replacement Therapy Market Drivers & Restraints
Rising awareness against smoking, rising demand for nicotine replacement therapy
Rising awareness against smoking and rising demand for nicotine replacement therapy (NRT) has become the major factor in target market growth. Rising awareness against smoking in individual has given rise in demand for nicotine replacement therapy. According to CDC (Centers for Disease Control and Prevention), approx. 68% of Americans has decided to stop smoking which will led to increase in NRT product sales in the coming years. Government initiative programs like ‘affordable care act’, various campaigns to provide knowledge about harmful effects of smoking, insurance requirements has contributed to give rise in the use of NRT. Increase in price of cigarettes and decrease in price of NRT products has led to substantial increase in per-capita sales of NRT products. NRT help to stop smoking. NRT has become more effective as it help nicotine dependent smokers who seek help in stopping. NRT works without counselling and do not need any prescription by doctor. Using NRT is much less likely to cause heart disease then continued smoking. If an individual continued to smoke instead of using NRT it will be exposed to hundreds of harmful chemicals in cigarette smoking. Mostly, people are well educated and are switching to more advanced goods due to rising technological advancement. Quitting smoking is beneficial to reduce the risk of cancer, chronic obstructive pulmonary disease (COPD), cardiovascular disease, etc. According to CDC using combination of nicotine replacement therapy can further increase the likelihood of quitting.
For instance, in 2022, Mumbai (India) Nicotine Replacement Therapy may become a part of essential medicines list. NRT is a WHO approved 12 week regimen which help in reducing smokers dependency on cigarettes gradually & finally led them to quit smoking. Daily NRT therapy cost ranges between Rs 10 to 13 per patient and taken over 60 to 90 days. Once added to NLEM (National List of Essential Medicines), it will boost the availability of NRT across the country at affordable prices with central & state agencies rolling out smoking cessation programmes. According to WHO, use of tobacco causes 8 million deaths every year and led to cancers, cardiovascular diseases, lung diseases, diabetes, etc., thus, quitting can be challenging. Around, 1.3 billion tobacco users globally as many 60% has expressed desire to quit, and 30% has accessed to tools to help them to do so successfully. In October 2021, WHO has announced the updated model list in which NRT (nicotine replacement therapy) was listed as an essential, effective medicine for the people who wish to quit or stop using tobacco, and it also helps in reducing nicotine withdrawal symptoms and two new tobacco cessation medicines Bupropian and Varenicline are added to WHO essential medicines list which has proved to be safe and effective. However, rising awareness against smoking and rising demand for NRT (nicotine replacement therapy) to quit smoking has boosts the demand for target market growth.
Restrains:
NRT can cause some side-effects like headache, dizziness, upset stomach, skin irritation caused due to patches, irritation of nose, eyes, throat due to nasal spray, insomnia, etc. Nicotine patches causes racing heartbeat, muscle aches and stiffness. Nicotine gum causes throat irritation, bad taste, nausea, hiccups, racing heartbeat, jaw discomfort, mouth sores, etc. Nicotine gum can stick to and damage dentures & dental work. Swallowing and chewing the nicotine too fast can cause stomach and jaw discomfort. Nicotine spray can causes side-effects like runny nose, nasal irritation, watery eyes, coughing. However, some side-effects caused by NRT may restrain the target market growth.
Nicotine Replacement Therapy Market Segmentations & Regional Insights
The Nicotine Replacement Therapy market is segmented based on type, distribution channel, and region.
On the basis of type, the Nicotine Replacement Therapy market is segmented into Inhalers, Lozenges, Gums, Patches, and others. On the basis of distribution channel, the target market is segmented into Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, and others.
Regional Insights:
Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.
On region the Nicotine Replacement Therapy Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period, owing to growing population, especially in countries such as Europe and Asia Pacific, and technological advancements. Moreover, rising addiction of tobacco smoking, rising prevalence of chronic disease, rising incidence of tobacco-associated diseases, well developed & robust healthcare infrastructure, presence of major key players, is anticipated to increase demand for Nicotine Replacement Therapy in the region.
Report Scope:
Attribute |
Details |
Market Size 2024 |
US$ 50.4 billion |
Projected Market Size 2034 |
US$ 181.4 billion |
CAGR Growth Rate |
13.70% |
Base year for estimation |
2023 |
Forecast period |
2024 – 2034 |
Market representation |
Revenue in USD Billion & CAGR from 2024 to 2034 |
Market Segmentation |
By Type - Inhalers, Lozenges, Gums, Patches, and others By Distribution Channel – Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, and others
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the Genomics Market report based on Type, Distribution Channel and region:
Nicotine Replacement Therapy Market, By Type:
- Inhalers
- Lozenges
- Gums
- Patches
- Others
Nicotine Replacement Therapy Market, By Distribution Channel:
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- Others
Nicotine Replacement Therapy Market, By Region:
- North America
- Middle East & Africa
-
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
-
- Latin America
-
- Brazil
- Mexico
- Rest of Latin America
-
- Asia Pacific
-
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
-
- Europe
-
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
-
-
- U.S.
- Canada
- Middle East & Africa
Nicotine Replacement Therapy Market Competitive Landscape & Key Players
The key players operating the Nicotine Replacement Therapy Market includes, Cipla Limited, Johnson & Johnson Inc., GlaxoSmithKline plc., Pfizer Inc., Glenmark Pharmaceuticals Limited., Rubicon Research Pvt. Ltd., Lucy Goods Inc., Fertin Pharma Ltd., Japan Tobacco Inc., British American Tobacco plc., and others.
Nicotine Replacement Therapy Market Recent News
Recent Development:
- In March 2022, Nicorette and NicoDerm has launched new updated consumer website with new design strategy to create master brand which will bring the products together as a portfolio of NRT (nicotine replacement therapy) solution across forms. New Nicorette.com website is launched which will serve as a digital ecosystem for smokers, and also help in improving the end to end consumer experience with trusted NRT products & services, and quit support tools for helping smokers to achieve their ultimate goal of being nicotine-free and smoke-free.
- In June 2021, Rubicon Research Pvt. Ltd., entered into strategic marketing partnership with Wellesta Holdings Thane, Mumbai (India). This marketing partnership will help in supporting the global business development efforts and focuses on proprietary & market leading range of Nicotine Lozenges (in 2mg & 4mg). This partnership has aimed to transform lives in Asia Pacific region by enabling & providing access to superior Nicotine Replacement Therapy product.
- In January 2021, Johnson & Johnson Inc., donate the nicotine patches to help thousands of Jordanians to quit tobacco during COVID-19. The Ministry of Health of Jordan has received first donation from Johnson & Johnson in nicotine replacement therapy.
Nicotine Replacement Therapy Market Company Profile
- Johnson & Johnson Inc.*
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Cipla Limited
- GlaxoSmithKline plc.
- Pfizer Inc.
- Glenmark Pharmaceuticals Limited.
- Rubicon Research Pvt. Ltd.*
- Lucy Goods Inc.
- Fertin Pharma Ltd.
- Japan Tobacco Inc.
- British American Tobacco plc.
“*” marked represents similar segmentation in other categories in the respective section
FAQs
The Nicotine Replacement Therapy Market is segmented into type, distribution channel, and region.
Nicotine Replacement Therapy Market is driven by factors like rising awareness against smoking and rising demand for nicotine replacement therapy (NRT).
By region, the Nicotine Replacement Therapy market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period, owing to growing population, especially in countries such as Europe and Asia Pacific, and technological advancements.
The key players operating the Nicotine Replacement Therapy Market includes, Cipla Limited, Johnson & Johnson Inc., GlaxoSmithKline plc., Pfizer Inc., Glenmark Pharmaceuticals Limited., Rubicon Research Pvt. Ltd., Lucy Goods Inc., Fertin Pharma Ltd., Japan Tobacco Inc., British American Tobacco plc., and others.